Lisa K. McNeil,Robert G. K. Donald,Alexey Gribenko,Roger French,Nathaniel Lambert,Shannon L. Harris,Thomas R. Jones,Sheng Li,Gary Zlotnick,Ulrich Vogel,Heike Claus,Raquel Abad,Julio A. Vazquez,Ray Borrow,Jamie Findlow,Muhamed-Kheir Taha,Ala-Eddine Deghmane,Dominique A. Caugant,Paula Kriz,Martin Musilek,Xin Wang,Jeni Vuong,Leonard W. Mayer,Michael W. Pride,Kathrin U. Jansen,Annaliesa S. Anderson,Jan Poolman,Holly Sanders,Shannon L Harris,Robert G K Donald,Dominique A Caugant,Leonard W Mayer,Michael W Pride,Lisa K McNeil,Thomas R Jones,Kathrin U Jansen,Julio A Vazquez,Annaliesa S Anderson

Abstract:Bivalent rLP2086 (Trumenba), a vaccine for prevention of Neisseria meningitidis serogroup B (NmB) disease, was licensed for use in adolescents and young adults after it was demonstrated that it elicits antibodies that initiate complement-mediated killing of invasive NmB isolates in a serum bactericidal assay with human complement (hSBA). The vaccine consists of two factor H binding proteins (fHBPs) representing divergent subfamilies to ensure broad coverage. Although it is the surrogate of efficacy, an hSBA is not suitable for testing large numbers of strains in local laboratories. Previously, an association between the in vitro fHBP surface expression level and the susceptibility of NmB isolates to killing was observed. Therefore, a flow cytometric meningococcal antigen surface expression (MEASURE) assay was developed and validated by using an antibody that binds to all fHBP variants from both fHBP subfamilies and accurately quantitates the level of fHBP expressed on the cell surface of NmB isolates with mean fluorescence intensity as the readout. Two collections of invasive NmB isolates ( n = 1,814, n = 109) were evaluated in the assay, with the smaller set also tested in hSBAs using individual and pooled human serum samples from young adults vaccinated with bivalent rLP2086. From these data, an analysis based on fHBP variant prevalence in the larger 1,814-isolate set showed that >91% of all meningococcal serogroup B isolates expressed sufficient levels of fHBP to be susceptible to bactericidal killing by vaccine-induced antibodies. IMPORTANCE Bivalent rLP2086 (Trumenba) vaccine, composed of two factor H binding proteins (fHBPs), was recently licensed for the prevention of N. meningitidis serogroup B (NmB) disease in individuals 10 to 25 years old in the United States. This study evaluated a large collection of NmB isolates from the United States and Europe by using a flow cytometric MEASURE assay to quantitate the surface expression of the vaccine antigen fHBP. We find that expression levels and the proportion of strains above the level associated with susceptibility in an hSBA are generally consistent across these geographic regions. Thus, the assay can be used to predict which NmB isolates are susceptible to killing in the hSBA and therefore is able to demonstrate an fHBP vaccine-induced bactericidal response. This work significantly advances our understanding of the potential for bivalent rLP2086 to provide broad coverage against diverse invasive-disease-causing NmB isolates.

Immunization with recombinant truncated Neisseria meningitidis-Macrophage Infectivity Potentiator (rT-Nm-MIP) protein induces murine antibodies that are cross-reactive and bactericidal for Neisseria gonorrhoeae

Outcomes After Elevation of Serratus Anterior Fascia During Prosthetic Breast Reconstruction

The serogroup B meningococcal outer membrane vesicle-based vaccine 4CMenB induces cross-species protection against Neisseria gonorrhoeae

Group B meningococcal outer membrane protein vaccine promote potent anti-viral effect

Bactericidal Antibody Responses to Meningococcal Recombinant Outer Membrane Proteins

Application of a Neisseria meningitidis antigen microarray to identify candidate vaccine proteins from a human Phase I clinical trial

Immunogenicity of antigens from outer membrane vesicles of Neisseria meningitidis associated with bilayer fragment of dioctadecyldimethylammonium in Swiss adult mice

Adjuvant-dependent impacts on vaccine-induced humoral responses and protection in preclinical models of nasal and genital colonization by pathogenic Neisseria

An Integrated in Silico Approach for the Identification of Novel Potential Drug Target and Chimeric Vaccine Against Neisseria Meningitides Strain 331401 Serogroup X by Subtractive Genomics and Reverse Vaccinology

Synthesis of a Glycolipidic Amphiphilic Nitrone as a New Spin Trap.

Assisting long-term patient recovery through a nonmonitored maintenance component in a cardiac rehabilitation program

Peptide Mimics of the Group B Meningococcal Capsule Induce Bactericidal and Protective Antibodies after Immunization

Preclinical evaluation of a novel group B meningococcal conjugate vaccine that elicits bactericidal activity in both mice and nonhuman primates.

New strategy to select cross-reactivity Meningococci strains: immunization with Outer membrane vesicles of serogroup C and cationic lipid as adjuvant

Highly Immunogenic Nanoparticles Based on a Fusion Protein Comprising the M2e of Influenza A Virus and a Lipopeptide

Neisseria gonorrhoeae lipooligosaccharide glycan epitopes recognized by bactericidal IgG antibodies elicited by the meningococcal group B-directed vaccine, MenB-4C

[Construction of the DNA Vaccine of Major Outer Membrane Protein of Neisseria Gonorrhoeae and Investigation of Immune Effects after Vaccination].

Tracheostomy in children: A population‐based experience over 17 years

Construction and protective immunogenicity of DNA vaccine pNMB0315 against Neisseria meningitidis serogroup B

Protection against nasopharyngeal colonization relies on antibody opsonization and phagocytosis by neutrophils

Predicting the Susceptibility of Meningococcal Serogroup B Isolates to Bactericidal Antibodies Elicited by Bivalent rLP2086, a Novel Prophylactic Vaccine.